Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.
The upward movement appears to be driven by recent analyst actions. Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on the stock and set a price target of $18.00, reinforcing positive sentiment towards the company's prospects.
Concurrently, Morgan Stanley adjusted its outlook, cutting its price target on Trevi Therapeutics to $18.00 from $19.00. Despite the reduction, the maintained target price suggests continued analyst confidence in the stock's value, contributing to the pre-market rally.